PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Am J Geriatr Pharmacother. Author manuscript; available in PMC Jun 27, 2012.
Published in final edited form as:
PMCID: PMC3384538
NIHMSID: NIHMS383825
Age-related Changes in Antidepressant Pharmacokinetics and Potential Drug-Drug Interactions: A Comparison of Evidence-Based Literature and Package Insert Information
Richard D. Boyce, PhD,1,2 Steven M. Handler, MD, PhD,1,2,3,4 Jordan F. Karp, MD,5 and Joseph T. Hanlon, PharmD, MS1,2,3,4,6,7
1Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA
2Geriatric Pharmaceutical Outcomes and Geroinformatics Research and Training Program, University of Pittsburgh, Pittsburgh, PA
3Division of Geriatric Medicine, University of Pittsburgh, Pittsburgh, PA
4Geriatric Research, Education and Clinical Center, and Center and the Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA
5Department of Psychiatry and Department of Anesthesiology, University of Pittsburgh, Pittsburgh, PA
6Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA
7Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA
Corresponding Author: Joseph T Hanlon, PharmD, MS, University of Pittsburgh, 3471 5th Ave, Kaufman Building-suite 500, Pittsburgh, PA 15213, Office#: (412) 864-2507, Fax#: 412-692-2370, jth14/at/pitt.edu
Keywords: antidepressants, aged, pharmacokinetics, drug interactions, drug product package inserts
Antidepressants are among the most commonly prescribed psychotropic agents for older patients. In particular, there has been a dramatic increase in the frequency at which antidepressants are prescribed to older nursing home patients. Specifically, antidepressant use has increased from 21.9% in 1996 to 47.5% in 2006.1 Of potential concern is that antidepressants are associated with an increased risk for potentially clinically significant adverse drug events (ADEs) in the elderly such as falls and fractures.2 The increased risk of ADEs might be due in part to dosing that does not take into account known age-related changes in antidepressant pharmacokinetics and/or drug-drug interactions (DDIs).34 Indeed a recently published study in 877 older nursing home patients showed that 43.1% of antidepressant prescribing for those with depression was potentially inappropriate.5 In particular, dosage problems were seen in 8.8% and DDIs in 25.9%. This latter point is important, as DDIs may be more common in older adults due to the greater number of medications needed to treat persons with multiple comorbid conditions.5
Thus prescribers are faced with a tension that requires that they consider the potential benefits and harms with the use of antidepressants in older patients. Therefore clinicians need accurate up to date pharmacotherapy information sources to correctly dose antidepressants and avoid potential DDIs with antidepressants. One potential source of pharmacotherapy information is the Food and Drug Administration (FDA) approved package inserts (PIs) for marketed antidepressants. However, previous work has shown that PIs for medications commonly used in hospitalized older adults rarely contain comprehensive information about age-related changes in pharmacokinetics.6 Moreover, two separate studies showed that only a minority of potentially clinically significant DDIs appear in the PI compared to other evidence-based sources.7,8 To the best of our knowledge, no study has compared antidepressant PI’s with the evidence-based primary scientific literature regarding the completeness of information about geriatric pharmacokinetics and DDIs.
Given this background, the objective of this study is to synthesize and contrast information in the PI versus that found in the scientific literature regarding antidepressants age-related changes in systemic clearance and potential pharmacokinetic DDIs.
Included Antidepressants and PI Retrieval
Currently-marketed antidepressants were identified by searching the Martindale drug reference for drugs indicated for the treatment of depression. Those listed in the “drugs@FDA” database were included in this study.9,10 Appendix A list the 26 agents available as of the start of our study (September, 2011). FDA-approved PIs were retrieved when possible for these 26 currently -marketed antidepressants from the 2011 Physicians’ Desk Reference® (PDR).11 In cases where we could find no relevant package insert in the PDR, one was retrieved from the National Library of Medicine’s DailyMed website.12
Appendix A
Appendix A
Antidepressants Included in This Study*
Age-related Pharmacokinetic Changes with Antidepressants
We identified published studies examining age-related pharmacokinetic changes affecting antidepressants by searching MEDLINE and EMBASE from January 1975 through September 2011. The searches combined the generic names of each antidepressant with the term “pharmacokinetics” and limited the results to studies published in English that included persons age ≥65. Additional articles were found by a manual search of the reference lists of identified articles and the authors’ files, book chapters, and recent review articles.1325 Two of the investigators (JTH and RDB) independently screened the search results for studies that compared the systemic clearance (Cl) of an antidepressant between the younger and older. We considered a drug to have an age-related change in Cl if any pharmacokinetic study reported a quantitative decrease in Cl in older adults as compared with younger adults. The same two investigators independently identified PI statements referring to age-related pharmacokinetic changes and reporting the quantitative difference in Cl of the antidepressant between the young and old study populations. PIs statements discussing the results of pharmacokinetic studies as “no effect” or “no change” were not included.” Any discordances were resolved by another author (SMH).
Pharmacokinetic Drug interactions with Antidepressants
We identified published studies examining pharmacokinetic DDIs affecting antidepressants by searching MEDLINE and EMBASE from January 1975 through September 2011. The searches combined the names of each antidepressant with the terms “clinical trial”, “drug interactions”, and “interaction.” and the results were limited to studies published in English. Additional articles were found by a manual search of the reference lists of identified articles and the authors’ files, book chapters, and recent review articles.1325 Studies involving precipitant drugs that are no longer marketed or cytochrome P450 (CYP) enzyme inducing agents were excluded. Two of the investigators (JTH and RDB) independently reviewed each study and included only those studies that measured systemic Cl and/or area under the concentration time curve (AUC) of the object antidepressant drug in the presence of a precipitant drug. A DDI was operationally defined as any increase in the AUC or decrease in Cl of an antidepressant in the presence of a precipitant drug. The same two investigators independently identified PIs for quantitative information regarding the impact of specific medications on antidepressant AUC and/or Cl. Any discordances were resolved by the another author (SMH).
Statistical Analysis
Descriptive statistics (i.e. percentages) were calculated for literature and PI derived studies showing evidence of age-related decline in systemic clearance and potential DDIs. Agreement between the literature or PI statements for both age-related pharmacokinetic changes and potential DDIs were calculated by the Kappa statistic (a measure of chance-adjusted agreement).26 A Kappa statistic of >0.75 was ranked as “excellent” agreement, one between 0.40 and 0.75 was considered “good to fair,” and less than 0.40 was considered to be “marginal” or “poor” agreement. The Kappa statistic was calculated using SAS (version 9.0, Cary, NC).
Table 1 shows the studies from the scientific literature regarding potential age-related changes in systemic Cl for the 26 antidepressants. It was determined that 13 of the 26 (50%) antidepressants had evidence of age-related decline in systemic Cl.2744
Table 1
Table 1
Evidence from the scientific literature about age-related reduction in systemic clearance of antidepressants
Table 2 shows information about age-related changes in Cl from PIs. The PIs provided sufficient information on age-related decline in systemic Cl for four antidepressants.4548. Overall, agreement between the literature and PI regarding age-related Cl changes was marginal or poor as indicated by a Kappa statistic of less than 0.40.
Table 2
Table 2
Evidence from the package insert about age-related reduction in systemic clearance of antidepressants
Our search also revealed 52 articles from the scientific literature involving 45 drug-antidepressant pairs that were deemed to be pharmacokinetic DDIs due to changes in AUC and/or Cl (Table 3).49101 In contrast, the PI shows that only 12 drug-antidepressant interactions involving 8 antidepressants as per changes in AUC or Cl parameter. (Table 4).4547, 102106 Again, overall agreement between the PIs and literature was marginal or poor with a Kappa statistic of less than 0.40.
Table 3
Table 3
Potential pharmacokinetic drug interactions with antidepressants from the scientific literature
Table 4
Table 4
Potential pharmacokinetic drug interactions with antidepressants from FDA-approved drug package labeling
This study demonstrated that the scientific literature provides more complete information regarding age-related decline in antidepressant systemic Cl than does the PI (50% of antidepressants vs 15%). These findings are concordant with a study by Steinmetz et al. found that only 8% of the 50 PIs for commonly used medications in hospitalized older adults stated age- or disease-related pharmacokinetic changes quantitatively.6 It is important to note that despite the marginal to poor overall agreement between the two information sources, the PI did identify two antidepressants with age-related decline in systemic Cl that were not identified in the literature (i.e., mirtazapine and duloxetine).46,47
This study also determined that the literature reported almost four times as many pharmacokinetic DDIs affecting AUC or Cl than did the PIs (47 vs 12). This is consistent with a study by Hines et al. that found that only 15% of the PIs for drugs commonly known to interact with warfarin stated so.7 Similarly, Chao and Maibach found that PIs contained only between 13–48% of the known DDIs affecting four commonly-prescribed dermatologic drugs (i.e., dapsone, erythromycin, methotrexate, and prednisone).8 In this study the PIs did however identify 4 potential DDIs not found in the literature (i.e., cimetidine-citalopram, ketoconazole-mirtazapine, cimetidine-sertraline, and ketoconazole-vilazodone).46,104106 Fortunately, neither cimetidine or ketoconazole are commonly used medications in older patients.5
Our review of the literature and PIs found twelve antidepressants that have evidence of both an age-related decrease in Cl and at least one Cl-reducing pharmacokinetic DDI. These include three SSRIs (citalopram, escitalopram, and sertraline), two SNRIs (duloxetine, venlafaxine,), four TCAs (amitriptyline, doxepin, imipramine, and nortriptyline) and three other newer antidepressants (bupropion, mirtazapine, and trazodone). Clinicians should be aware that the combination of two or more factors reducing drug clearance can increase the chance that their elderly patient will experience an adverse drug event.4,107 This phenomena was seen in a study by Zint et al. that examined the association between benzodiazepines and hip fracture among older adults.108 Specifically the association between alprazolam alone and falls was not statistically significant (Adjusted Relative Risk [ARR] 1.01, 95% confidence interval [CI] 0.92–1.11). However, the combination of alprazolam with an interacting drug resulted in a point estimate for risk that was increased by nearly 50% (RR 1.51, 1.34–1.69).108
Our study has a number of potential limitations. One potential limitation of this study is that we excluded drug interactions with possible pharmacokinetic and/or pharmacodynamic mechanisms that were found by observational studies. In addition, no distinction was made between age-related changes in free systemic clearance versus clinically important decline. Moreover, we included DDI studies that observed any decrease in Cl or increase in AUC, even if the difference between groups did not reach statistical significance (p<0.05). Nonetheless, we believe that using these more sensitive approaches for inclusion was justified due to the small number of subjects in these studies which could have limited their statistical power to detect meaningful differences. Finally, our search strategy might have missed some studies published in languages other than English, and studies available in unpublished technical reports, white papers, or other “grey literature” sources.
CONCLUSIONS
The evidence-based literature compared to PIs is the most complete pharmacotherapy information source regarding both age-related Cl changes and pharmacokinetic DDIs with antidepressants. Future rigorously designed observational studies are needed to examine the combined risk of antidepressants with age-related decline in clearance and potential DDIs on important health outcomes such as falls and fractures in older patients. 108,109
Acknowledgments
We would like to thank Subashan Perera, PhD for his help calculating the Kappa statistics.
The first author (RDB) was funded by grant K12HS019461 from the Agency for Healthcare Research and Quality. Additional grant support for the co-authors was provided by an Agency for Healthcare Research and Quality grant (R01HS018721 and R01 HS017695), National Institute on Aging grants (K07AG033174, P30AG024827, T32 AG021885, R01AG034056, R56AG0207017 and AG033575), a National Institute of Nursing Research grant (R01 NR010135), National Center for Research Resources grants (KL2 RR024154, 3 UL1 RR024153-04S4), and a VA Health Services Research grant (IIR-06-062). The content is solely the responsibility of the authors and does not represent the official views of the Agency for Healthcare Research and Quality or any of the other funding sources.
Footnotes
CONFLICT OF INTEREST STATEMENT
The authors acknowledge no conflicts of interest. JK has been an advisor for Eli Lilly and Theravance, but not within the last 18 months. He is also a stock owner of Corcept.
1. Hanlon JT, Handler SM, Castle NG. Antidepressant prescribing in US nursing homes between 1996 and 2006 and its relationship to staffing patterns and use of other psychotropic medications. J Am Med Dir Assoc. 2010;11:320–324. [PMC free article] [PubMed]
2. Bharucha A, Borson S. Mood Disorders. In: Reichman W, Katz P, editors. Psychiatry in long-term care. 2. New York, NY: Oxford University Press; 2009. pp. 67–128.
3. Pollock B, Forsyth C, Bies R. The critical role of clinical pharmacology in geriatric psychopharmacology. Clin Pharmacol Ther. 2009;85:89–93. [PubMed]
4. Preskorn SH, Flockhart D. 2010 Guide to Psychiatric Drug Interactions. Primary Psychiatry. 2009;16:45–74.
5. Hanlon JT, Wang X, Castle NG, Stone RA, Handler SM, Semla TP, Pugh MJ, Berlowitz DR, Dysken MW. Potential underuse, overuse and inappropriate use of antidepressants in older veteran nursing home patients. J Am Geriatr Soc. 2011;59:1412–20. [PMC free article] [PubMed]
6. Steinmetz KL, Coley KC, Pollock BG. Assessment of geriatric information on the drug label for commonly prescribed drugs in older people. J Am Geriatr Soc. 2005;53:891–894. [PubMed]
7. Hines LE, Ceron-Cabrera D, Romero K, et al. Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs. Clin Ther. 2011;33:36–45. [PubMed]
8. Chao SD, Maibach HI. Lack of drug interaction conformity in commonly used drug compendia for selected at-risk dermatologic drugs. Am J Clin Dermatol. 2005;6:105–111. [PubMed]
9. Sweetman S. Martindale: The Complete Drug Reference. 36. Palo Alto, CA: Pharmaceutical Press; 2009.
10. FDA. [Accessed June 7, 2011];Drugs@FDA. 2011 Available at: http://wwwaccessdatafdagov/scripts/cder/drugsatfda/
11. Physicians’ Desk Reference. 64. Montvale, NJ: Thomson PDR; 2010.
12. National Library of Medicine. [Accessed July 1, 2011];DailyMed. website ( http://dailymed.nlm.nih.gov)
13. Salzman C. Clinical Geriatric Psychopharmacology. 4. Philadelphia PA: Lippincott Williams & Wilkins; 2004.
14. von Moltke LL, Greenblatt DJ, Shader RI. Clinical pharmacokinetics of antidepressants in the elderly: Therapeutic implications. Clin Pharmacokinet. 1993;24:141–160. [PubMed]
15. Hrdina PD, Hutchinson LJ, Lapierre YD, et al. Pharmacokinetics of psychotropic drugs: what can it tell us? Prog Neuropsychopharmacol Biol Psychiatry. 1982;6:681–688. [PubMed]
16. Furlanut M, Benetello P. The pharmacokinetics of tricyclic antidepressant drugs in the elderly. Pharmacol Res. 1990;22:15–25. [PubMed]
17. Muijsers RBR, Plosker GL, Noble S. Sertraline: a review of its use in the management of major depressive disorder in elderly patients. Drugs Aging. 2002;19:377–392. [PubMed]
18. Gareri P, Falconi U, De Fazio P, et al. Conventional and new antidepressant drugs in the elderly. Prog Neurobiol. 2000;61:353–396. [PubMed]
19. DeVane CL, Pollock BG. Pharmacokinetic considerations of antidepressant use in the elderly. J Clin Psychiatry. 1999;60 (Suppl 20):38–44. [PubMed]
20. DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin Pharmacokinet. 2002;41:1247–1266. [PubMed]
21. Cutler NR, Narang PK. Implications of dosing tricyclic antidepressants and benzodiazepines in geriatrics. Psychiatr Clin North Am. 1984;7:845–861. [PubMed]
22. Greene DS, Barbhaiya RH. Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet. 1997;33:260–275. [PubMed]
23. Spina E, Santoro V, D’Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008;30:1206–1227. [PubMed]
24. Sandson NB, Armstrong SC, Cozza KL. An overview of psychotropic drug-drug interactions. Psychosomatics. 2005;46:464–494. [PubMed]
25. Ciraulo DA, Shader RI, Greenblatt DJ, et al. Drug Interactions in Psychiatry. 3. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
26. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174. [PubMed]
27. Sweet RA, Pollock BG, Kirshner M, et al. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol. 1995;35:876–884. [PubMed]
28. Greenblatt DJ, Friedman H, Burstein ES, et al. Trazodone kinetics: effect of age, gender, and obesity. Clin Pharmacol Ther. 1987;42:193–200. [PubMed]
29. Bayer AJ, Pathy MS, Ankier SI. Pharmacokinetic and pharmacodynamic characteristics of trazodone in the elderly. Br J Clin Pharmacol. 1983;16:371–376. [PubMed]
30. Klamerus KJ, Parker VD, Rudolph RL, et al. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy. 1996;16:915–923. [PubMed]
31. Reis M, Lundmark J, Bengtsson F. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992–1997. Ther Drug Monit. 2003;25:183–191. [PubMed]
32. Gutierrez M, Abramowitz W. Steady-state pharmacokinetics of citalopram in young and elderly subjects. Pharmacotherapy. 2000;20:1441–1447. [PubMed]
33. Bies RR, Feng Y, Lotrich FE, et al. Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. J Clin Pharmacol. 2004;44:1352–1359. [PubMed]
34. Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet. 1997;32 (Suppl 1):22–30. [PubMed]
35. Hrdina PD, Rovei V, Henry JF, et al. Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. Psychopharmacology (Berl) 1980;70:29–34. [PubMed]
36. Henry JF, Altamura C, Gomeni R, et al. Pharmacokinetics of amitriptyline in the elderly. Int J Clin Pharmacol Ther Toxicol. 1981;19:1–5. [PubMed]
37. Schulz P, Turner-Tamiyasu K, Smith G, et al. Amitriptyline disposition in young and elderly normal men. Clin Pharmacol Ther. 1983;33:360–366. [PubMed]
38. Ogura C, Kishimoto A, Mizukawa R, et al. Age differences in effects on blood pressure, flicker fusion frequency, salivation and pharmacokinetics of single oral doses of dothiepin and amitriptyline. Eur J Clin Pharmacol. 1983;25:811–814. [PubMed]
39. Abernethy DR, Greenblatt DJ, Shader RI. Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther. 1985;232:183–188. [PubMed]
40. Meyer-Barner M, Meineke I, Schreeb KH, et al. Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the population approach. Eur J Clin Pharmacol. 2002;58:253–257. [PubMed]
41. Ereshefsky L, Tran-Johnson T, Davis CM, et al. Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine--new data and review. Clin Chem. 1988;34:863–880. [PubMed]
42. Benetello P, Furlanut M, Zara G, et al. Imipramine pharmacokinetics in depressed geriatric patients. Int J Clin Pharmacol Res. 1990;10:191–195. [PubMed]
43. Jerling M, Merlé Y, Mentré F, et al. Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method. Br J Clin Pharmacol. 1994;38:453–462. [PubMed]
44. Dawling S, Crome P, Braithwaite RA, et al. Nortriptyline therapy in elderly patients: dosage prediction after single dose pharmacokinetic study. Eur J Clin Pharmacol. 1980;18:147–150. [PubMed]
45. Wellbutrin SR (bupropion hydrochloride) tablet, film coated [package insert] Research Triangle Park, NC: GlaxoSmithKline LLC; 2011.
46. Remeron (mirtazapine) tablet, film coated [package insert] Roseland, NJ: Organon Pharmaceuticals USA; 2011.
47. Cymbalta (duloxetine hydrochloride) capsule, delayed release [package insert] Indianapolis, IN: Eli Lilly and Company; 2010.
48. Sertraline hydrochloride tablet [package insert] Corona, CA: Watson Laboratories, Inc; 2008. [Accessed July 14, 2011]. Available at: http://dailymednlmnihgov/dailymed/lookupcfm?setid=a8b2ad71-cfdc-4a29-8194-deefea138b16.
49. Azzaro AJ, Ziemniak J, Kemper E, et al. Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications. J Clin Pharmacol. 2007;47:146–158. [PubMed]
50. Dostert P, Strolin Benedetti M, Persiani S, et al. Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline. J Neural Transm Suppl. 1995;45:247–257. [PubMed]
51. Laine K, Anttila M, Heinonen E, et al. Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol. 1997;20:419–433. [PubMed]
52. Kivistö KT, Wang JS, Backman JT, et al. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol. 2001;57:37–42. [PubMed]
53. Kustra R, Corrigan B, Dunn J, et al. Lack of effect of cimetidine on the pharmacokinetics of sustained-release bupropion. J Clin Pharmacol. 1999;39:1184–1188. [PubMed]
54. Turpeinen M, Tolonen A, Uusitalo J, et al. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2005;77:553–559. [PubMed]
55. Farid NA, Payne CD, Ernest CS, 2nd, et al. Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. J Clin Pharmacol. 2008;48:53–59. [PubMed]
56. Hesse LM, Greenblatt DJ, von Moltke LL, et al. Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers. J Clin Pharmacol. 2006;46:567–576. [PubMed]
57. Park J, Vousden M, Brittain C, et al. Dose-related reduction in bupropion plasma concentrations by ritonavir. J Clin Pharmacol. 2010;50:1180–1187. [PubMed]
58. Sennef C, Timmer CJ, Sitsen JMA. Mirtazapine in combination with amitriptyline: a drug-drug interaction study in healthy subjects. Hum Psychopharmacol. 2003;18:91–101. [PubMed]
59. Sitsen JM, Maris FA, Timmer CJ. Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects. Eur J Clin Pharmacol. 2000;56:389–394. [PubMed]
60. Sitsen JM, Voortman G, Timmer CJ. Pharmacokinetics of mirtazapine and lithium in healthy male subjects. J Psychopharmacol (Oxford) 2000;14:172–176. [PubMed]
61. Ruwe FJL, Smulders RA, Kleijn HJ, et al. Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjects. Hum Psychopharmacol. 2001;16:449–459. [PubMed]
62. Barbhaiya RH, Shukla UA, Greene DS. Lack of interaction between nefazodone and cimetidine: a steady state pharmacokinetic study in humans. Br J Clin Pharmacol. 1995;40:161–165. [PubMed]
63. Khan AY, Preskorn SH, Horst WD. Coadministration of nefazodone and desipramine: a pharmacokinetic interaction study. J Pak Med Assoc. 2007;57:230–235. [PubMed]
64. Laroudie C, Salazar DE, Cosson JP, et al. Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects. Eur J Clin Pharmacol. 1999;54:923–928. [PubMed]
65. Greene DS, Salazar DE, Dockens RC, et al. Coadministration of nefazodone and benzodiazepines: IV A pharmacokinetic interaction study with lorazepam. J Clin Psychopharmacol. 1995;15:409–416. [PubMed]
66. Farkas D, Volak LP, Harmatz JS, et al. Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. Clin Pharmacol Ther. 2009;85:644–650. [PubMed]
67. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol. 2003;43:414–422. [PubMed]
68. Lobo ED, Bergstrom RF, Reddy S, et al. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet. 2008;47:191–202. [PubMed]
69. Skinner MH, Kuan H-Y, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther. 2003;73:170–177. [PubMed]
70. Troy SM, Rudolph R, Mayersohn M, et al. The influence of cimetidine on the disposition kinetics of the antidepressant venlafaxine. J Clin Pharmacol. 1998;38:467–474. [PubMed]
71. Lessard E, Yessine MA, Hamelin BA, et al. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. J Clin Psychopharmacol. 2001;21:175–184. [PubMed]
72. Lindh JD, Annas A, Meurling L, et al. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine. Eur J Clin Pharmacol. 2003;59:401–406. [PubMed]
73. Hynninen V-V, Olkkola KT, Bertilsson L, et al. Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine. Clin Pharmacol Ther. 2008;83:342–348. [PubMed]
74. Gutierrez M, Abramowitz W. Lack of effect of a single dose of ketoconazole on the pharmacokinetics of citalopram. Pharmacotherapy. 2001;21:163–168. [PubMed]
75. Malling D, Poulsen MN, Søgaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol. 2005;60:287–290. [PubMed]
76. Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther. 2003;25:1200–1210. [PubMed]
77. D’Souza DL, Dimmitt DC, Robbins DK, et al. Effect of alosetron on the pharmacokinetics of fluoxetine. J Clin Pharmacol. 2001;41:455–458. [PubMed]
78. Gupta S, Banfield C, Kantesaria B, et al. Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers. J Clin Pharmacol. 2004;44:1252–1259. [PubMed]
79. Bannister SJ, Houser VP, Hulse JD, et al. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatr Scand. 1989;350:102–106. [PubMed]
80. Yasui-Furukori N, Saito M, Inoue Y, et al. Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. Eur J Clin Pharmacol. 2007;63:51–56. [PubMed]
81. Nagy CF, Kumar D, Perdomo CA, et al. Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses. Br J Clin Pharmacol. 2004;58 (Suppl 1):25–33. [PubMed]
82. Curry SH, DeVane CL, Wolfe MM. Cimetidine interaction with amitriptyline. Eur J Clin Pharmacol. 1985;29:429–433. [PubMed]
83. Dugal R, Caille G, Albert JM, et al. Apparent pharmacokinetic interaction of diazepam and amitriptyline in psychiatric patients: a pilot study. Curr Ther Res Clin Exp. 1975;18:679–686. [PubMed]
84. Wong SL, Cavanaugh J, Shi H, et al. Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Clin Pharmacol Ther. 1996;60:48–53. [PubMed]
85. Vezmar S, Miljkovic B, Vucicevic K, et al. Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression. J Pharmacol Sci. 2009;110:98–104. [PubMed]
86. Venkatakrishnan K, Schmider J, Harmatz JS, et al. Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. J Clin Pharmacol. 2001;41:1043–1054. [PubMed]
87. Zhi J, Moore R, Kanitra L, et al. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol. 2002;42:1011–1019. [PubMed]
88. Sauer J-M, Long AJ, Ring B, et al. Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome. J Pharmacol Exp Ther. 2004;308:410–418. [PubMed]
89. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther. 1992;51:239–248. [PubMed]
90. Preskorn SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol. 1994;14:90–98. [PubMed]
91. Spina E, Avenoso A, Campo GM, et al. Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. Br J Clin Pharmacol. 1997;43:315–318. [PubMed]
92. Brøsen K, Hansen JG, Nielsen KK, et al. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol. 1993;44:349–355. [PubMed]
93. Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol. 1997;17:284–291. [PubMed]
94. Boni J, Abbas R, Leister C, et al. Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus. Cancer Chemother Pharmacol. 2009;64:263–270. [PubMed]
95. Abernethy DR, Todd EL. Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. J Clin Psychopharmacol. 1986;6:8–12. [PubMed]
96. Abernethy DR, Greenblatt DJ, Shader RI. Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. J Pharmacol Exp Ther. 1984;229:702–705. [PubMed]
97. Wells BG, Pieper JA, Self TH, et al. The effect of ranitidine and cimetidine on imipramine disposition. Eur J Clin Pharmacol. 1986;31:285–290. [PubMed]
98. Henauer SA, Hollister LE. Cimetidine interaction with imipramine and nortriptyline. Clin Pharmacol Ther. 1984;35:183–187. [PubMed]
99. Hermann DJ, Krol TF, Dukes GE, et al. Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine. J Clin Pharmacol. 1992;32:176–183. [PubMed]
100. Albers LJ, Reist C, Helmeste D, et al. Paroxetine shifts imipramine metabolism. Psychiatry Res. 1996;59:189–196. [PubMed]
101. Laine K, Tybring G, Härtter S, et al. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001;70:327–335. [PubMed]
102. Oleptro (trazodone hydrochloride) extended-release tablets [package insert] Dublin Ireland: Labopharm; 2010.
103. Effexor (venlafaxine hydrochloride) capsule, extended release [package insert] Thousand Oaks, CA: Rebel Distributors Corp; 2010. [Accessed July 14, 2011]. Available at: http://dailymednlmnihgov/dailymed/lookupcfm?setid=8a2302ca-5c25-4d2d-9ffe-320080934aab.
104. Celexa (citalopram hydrobromide) tablet/solution [package insert] St Louis, MO: Forest Pharmaceuticals, Inc; 2009. [Accessed July 14, 2011]. Available at: http://dailymednlmnihgov/dailymed/lookupcfm?setid=4259d9b1-de34-43a4-85a8-41dd214e9177.
105. Lexapro (escitalopram oxalate) tablet, film coated/liquid [package insert] St Louis, MO: Forest Laboratories, Inc; 2011.
106. Viibryd (vilazodone hydrochloride) tablet, film coated [package insert] St Louis, MO: Forest Laboratories Inc; 2011. [Accessed July 14, 2011]. Available at: http://dailymednlmnihgov/dailymed/lookupcfm?setid=4c55ccfb-c4cf-11df-851a-0800200c9a66.
107. de Leon J, Spina E, Diaz FJ. Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians. J Clin Psychopharmacol. 2009;29:201–205. [PubMed]
108. Zint K, Haefeli WE, Glynn RJ, Mogun H, Avorn J, Stürmer T. Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiol Drug Saf. 2010;19:1248–55. [PubMed]
109. Hines LE, Murphy JE. Potentially harmful drug–drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011;9:364–377. [PubMed]